In SLE, antiplatelet autoantibodies—predominantly of the IgG subclass—target platelet surface glycoproteins, including GpIIb/IIIa, GpIa/IIa, and GPIbIX, promoting splenic phagocytosis and subsequent thrombocytopenia despite preserved or increased megakaryocyte counts in the bone marrow [1]. This evidence concerns the gene ITGA2B and systemic lupus erythematosus.